Skip to main content
. 2016 Oct 17;5(10):e004310. doi: 10.1161/JAHA.116.004310

Figure 1.

Figure 1

Temporal changes in use of NOACs compared with VKAs among patients on chronic OAC therapy undergoing PCI during the study period. Note the brisk increase in use of NOACs in place of VKAs beginning in 2010, which corresponds with the market approval of the first NOAC. NOAC indicates non‐vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; VKA, vitamin K antagonist.